Business Context and Reporting Period
Company: Illumina, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2000
Business Overview: Illumina is an early-stage biotechnology company developing next-generation tools (BeadArray technology) for the large-scale analysis of genetic variation and function. The company targets life sciences, pharmaceutical, agriculture, and food industries. As of the reporting date, the company had no commercially available products and generated revenue primarily from government grants and strategic partnerships.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2000 | Six Months Ended June 30, 1999 |
|---|---|---|
| Revenue | $161,857 | $172,096 |
| Net Loss | $(10,115,396) | $(1,960,914) |
| Net Loss Per Share (Basic/Diluted) | $(4.27) | $(1.80) |
| Cash and Cash Equivalents (End of Period) | $19,595,187 | $3,517,202 |
| Total Investments | $11,544,891 | $11,924,163 |
| Total Current Assets | $32,072,232 | $33,493,045 |
| Total Current Liabilities | $1,415,555 | $612,408 |
| Stockholders' Equity | $27,507,392 | $32,032,250 |
| Accumulated Deficit | ~$16.8 million | Not explicitly stated for 1999 |
Cash Flow (Six Months Ended June 30, 2000):
- Net cash used in operating activities: $(2,803,978)
- Net cash used in investing activities: $(881,191)
- Net cash provided by financing activities: $2,116,242
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 6% to $162,000 for the six months ended June 30, 2000, compared to $172,000 in the prior year period. Revenue remains almost entirely derived from government grants (95% in 2000 vs. 100% in 1999).
- Significant Increase in Expenses: Total costs and expenses surged from $2.32 million to $11.26 million.
- R&D Expenses: Increased by $5.13 million to $6.67 million. This includes a one-time $1.625 million charge for the acquisition of in-process technologies in March 2000.
- Non-Cash Compensation: Amortization of deferred compensation and other non-cash charges increased by $2.8 million to $3.04 million, driven by increased staffing and higher deemed fair value of stock.
- G&A Expenses: Increased by $1.0 million to $1.56 million due to staffing increases to support growth.
- Net Loss Expansion: Net loss widened significantly to $10.12 million from $1.96 million in the prior year period.
- Balance Sheet Strength: Despite the operating loss, cash and cash equivalents increased significantly to $19.6 million (from $3.5 million in the prior year period) due to financing activities and investment maturities.
Guidance, Outlook, and Risks
- Initial Public Offering (IPO): Subsequent to the reporting period, on July 28, 2000, the company completed an IPO selling 6,000,000 shares at $16.00, raising net proceeds of approximately $88.0 million. An over-allotment option was exercised on August 2, 2000, raising an additional $13.4 million.
- Liquidity Outlook: Management believes the IPO proceeds combined with existing cash ($31.1 million total liquid assets as of June 30) and strategic funding will be sufficient to fund operations for at least the next 24 months.
- Commercialization Timeline: The company expects to commercialize its first products in 2001 in partnership with PE Biosystems. No revenue from product sales has been generated to date.
- Risks and Contingencies:
- Profitability: The company expects to continue to incur net losses and may not achieve profitability. An accumulated deficit of $16.8 million existed as of June 30, 2000.
- Market Acceptance: Success depends on the emergence of markets for genetic analysis and the adoption of unproven technology.
- Manufacturing: The company has limited manufacturing experience and relies on third-party manufacturers or internal development for commercial scale production.
- Partnership Dependency: Commercialization relies heavily on partnerships (e.g., PE Biosystems); failure of these partnerships could halt product development.
- Capital Needs: Additional capital may be required sooner than anticipated if operating plans change or if commercialization is delayed.
Investor Verification Checklist
- Revenue Sustainability: Verify the status of government grants and strategic partnership funding, as product sales revenue is currently zero.
- One-Time Charges: Confirm the impact of the $1.625 million in-process technology acquisition charge on future R&D capitalization policies.
- Stock-Based Compensation: Review the amortization schedule for the $21 million cumulative deferred stock compensation, which significantly impacts reported net loss.
- Capital Expenditures: Monitor the $6.2 million secured loan commitment and $1.5 million letter of credit required for the new 97,000 sq. ft. facility lease.
- Partnership Progress: Track the development milestones with PE Biosystems for the 2001 product launch.